Dow Jones 30 Stocks SEC Filings — April 30, 2026
Across 50 SEC filings for the USA Dow Jones 30 intelligence stream (period April 30, 2026), Q1 2026 results dominate with 25+ earnings reports showing aggregate revenue growth of ~12% YoY (e.g., Caterpillar +22%, Quanta +26%, Merck +5%) but mixed profitability due to one-offs like impairments (Bausch $1.4B goodwill) and R&D spikes (Viking +263%). Margin trends reveal compression in 14/30 high-materiality filers (avg -150 bps, e.g., CNH Ag 440 bps drop), offset by expansions in banks (Pioneer NIM +9 bps) and insurers (Hippo combined ratio -60 pts). M&A activity surges with 12+ deals (e.g., Nvni 7 acquisitions, Pioneer 3), while capital allocation favors returns (18/50 announce buybacks/dividends, e.g., Southside $0.36 div, Quanta raised guidance). Guidance raised in 10/20 cases (e.g., Hippo GWP +$25-75M, Indivior rev +$90-90M), signaling resilience amid macro headwinds. Biotech fundraises extend runways (Intellia to 2028), but ongoing losses flag cash burn risks. Portfolio implication: overweight industrials (backlogs $48B Quanta), monitor banks for NIM/expenses, avoid high-impairment pharma.